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Abstract Persistent black holes (PBH) are associated
with axonal loss and disability progression in multiple
sclerosis (MS). The objective of this work was to determine
if BHT-3009, a DNA plasmid-encoding myelin basic pro-
tein (MBP), reduces the risk of new lesions becoming PBH,
compared to placebo, and to test if pre-treatment serum
anti-MBP antibody levels impact on the effect of BHT-
3009 treatment. In this retrospective, blinded MRI study,
we reviewed MRI scans of 155 MS patients from a double-
blind, randomized, phase II trial with three treatment arms
(placebo, 0.5 and 1.5 mg BHT-3009). New lesions at
weeks 8 and 16 were tracked at week 48 and those
appearing as T1-hypointense were classified as PBH. A
subset of 46 patients with available pre-treatment serum
anti-MBP IgM levels were analyzed separately. Overall,
there was no impact of treatment on the risk for PBH.
However, there was a significant interaction between anti-
MBP antibodies and treatment effect: patients receiving
0.5 mg BHT-3009 showed a reduced risk of PBH with
higher antibody levels compared to placebo (p \ 0.01).
Although we found no overall reduction of the risk for
PBH in treated patients, there may be an effect of low-dose
BHT-3009, depending on the patients’ pre-treatment
immune responses.
Part of the results of this study was presented as a poster-presentation
at the 25th Congress of the European committee for treatment and
research in multiple sclerosis (ECTRIMS) in Du¨sseldorf, Germany, in
September 2009. Session: immunomodulation-2, P820: ‘‘Conversion
of new inflammatory lesions to persistent black holes in patients with
relapsing multiple sclerosis participating in a phase II trial of DNA
vaccine encoding myelin basic protein (BHT-3009)’’.
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Abbreviations
ABH Acute black holes
CL Candidate lesions
CSF Cerebrospinal fluid
EDSS Expanded Disability Status Scale
Gd Gadolinium
MBP Myelin basic protein
MS Multiple sclerosis
MSSS MS Severity Score
MTR Magnetization transfer ratio
NAA N-Acetyl aspartate
NAGM Normal appearing grey matter
NAWM Normal appearing white matter
NUM Number of human MBP peptide epitopes
recognized by serum antibodies
PBH Persistent black holes
PD-w SE Proton density-weighted sequence
RRMS Relapsing remitting multiple Sclerosis
T1-w SE T1-weighted sequence
Introduction
Several studies using pathologic [1–4] and radiological
[5–11] measures suggest that T1-hypointense lesions in
multiple sclerosis (MS) (‘‘black holes’’) are associated with
more severe myelin and axonal loss. There is evidence for
cross-sectional and longitudinal correlations of T1-hypo-
intense-lesion load with clinical disability [10, 12–21].
The majority of new active MS lesions (65–80%)
[22] initially appear as hypointense on the unenhanced
T1-weighted image (acute black holes, ABH), probably
because of edema, as well as early de- and remyelination.
When the edema resolves and repair mechanisms take
place, the T1-signal may gradually return to isointense.
However, up to 40% [23] of ABH remain hypointense over
time (persistent black holes, PBH). Published post hoc
analyses of phase II trials suggested that this proportion is
lower with some established [24, 25] and experimental
agents [26, 27].
BHT-3009 is an experimental treatment for MS. It is a
DNA vaccine that encodes full-length human myelin basic
protein (MBP) and might induce antigen-specific tolerance.
In a placebo-controlled phase II trial with 289 RRMS
patients, a reduction of disease activity, assessed by MRI
measures, was shown for low-dose (0.5 mg) BHT-3009
[28]. Given BHT-3009’s proposed mechanism of action, it
may be most effective in patients with strong pre-treatment
anti-MBP immune responses. Indeed, higher levels of pre-
treatment anti-myelin basic protein (anti-MBP) antibodies
in the cerebrospinal fluid (CSF) as well as in serum cor-
related with a reduction in MRI activity [28] and a
reduction in MRI and clinical activity (relapse rate) [29],
respectively.
Using the MRI data from the phase II trial, we aimed to
determine the effect of BHT-3009 on the evolution of new
inflammatory lesions (candidate lesions, CL) into PBH. We
hypothesized that treatment with BHT-3009 reduces the
risk of developing PBH compared to placebo. We then
performed an exploratory analysis to examine potential
treatment effects (1) in different lesions subgroups (gado-
linium-enhancing CL and ABH) and (2) regarding different
types of PBH (reduction of risk of large and strongly
hypointense PBH).
A second objective of this study was to examine whether
a potential effect of BHT-3009 on the evolution of new
lesions to persistent black holes changes with pre-treatment
anti-MBP antibody levels. For this objective, we used the
antibody levels in serum and hypothesized that patients
with higher antibody levels would benefit more from
treatment with BHT-3009.
Methods
Patient population
In the placebo-controlled, double-blind, multicenter phase
II trial with BHT-3009 [28], 289 RRMS patients were
randomly assigned 1:1:1 to receive intramuscular injec-
tions of either 0.5 mg BHT-3009, 1.5 mg BHT-3009, or
placebo. The study has been performed in accordance with
the ethical standards laid down in the 1964 Declaration of
Helsinki and approved from the local ethical standards
committee. All persons gave their informed consent prior
to their inclusion in the phase II study. BHT-3009 was
administered every 2 weeks for the first 4 weeks, then
every 4 weeks thereafter for a total of 13 doses (44 weeks).
Inclusion and exclusion criteria have been fully described
elsewhere [28]. We performed a blinded-to-treatment
assignment analysis of 157 out of the 289 patients, who had
C1 new T2-lesion at week 8 and/or week 16 (CL). Two
patients with a total of 13 CL were excluded because of
insufficient MRI data (final n = 155). The clinical,
demographic, and imaging characteristics of the 155
patients included in this analysis are presented in Table 1.
Blood from 87 patients participating in the phase II
study had been collected at week 0 and the levels of anti-
MBP IgM antibodies were measured in serum using pep-
tide microarrays. The number of human MBP peptide
epitopes recognized by serum antibodies (NUM) was cal-
culated for each subject [29].
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The subgroup of patients with C1 CL and available
serum anti-MBP IgM levels (n = 46) was used to inves-
tigate the combined effects of BHT-3009 treatment and
pre-treatment antibody levels on the evolution of PBH.
MRI acquisition protocol
All patients underwent MR imaging of the brain at
screening, week 8, week 16, and monthly between week 28
and 48, according to a standardized protocol using a
1.5-Tesla magnet and applying the following sequences:
proton density-weighted (PD-w: repetition time, TR:
2,800–3,800, echo time, TE: 14–40), T2-w conventional spin
echo (TR: 2,800–3,800, TE: 80–120) and T1-w sequences
(spin echo sequences, TR: 500–650, TE: 10–20), before and
5–10 min after the administration of gadolinium diethyl-
enetriamine pentaacetate (Gd-DTPA 0.1 mmol/kg BW over
2 min). For all sequences, axial oblique contiguous 3-mm
Table 1 Baseline
characteristics of the 155
patients included in this study
(patients with at least one CL at
week 8 or 16)
EDSS Expanded Disability
Status Scale, CL candidate
lesions, Gd gadolinium, ABH
acute black holes
Note that age, disease duration,
number of relapses in the
previous 2 years, EDSS, T2-
and T1-hypointense lesion load
were assessed at week 0 of the
phase II study, whereas the
number of candidate lesions
(CL), acute black holes (ABH)
and Gd-enhancing CLs per
patient refer to week 8 and 16 of
the study (time-point of the
detection of CLs)
Characteristics Placebo 0.5 mg BHT-3009 1.5 mg BHT-3009 p
n = 50 n = 57 n = 48
Gender (F/M) 38/12 41/16 31/17 0.5
Age (years)
Mean 36.68 33.39 35.38 0.2
Median 37.5 33 35.5
Range 19–54 18–54 18–54
Disease duration (years)
Mean 6.11 5.05 5.16 0.5
Median 5.13 3.37 3.47
Range 0.50–20.23 0.32–21.50 0.32–25.16
Number of relapses in previous 2 years
Mean 1.92 2 2.19 0.3
Median 2 2 2
Range 1–4 1–4 1–8
EDSS
Mean 2.44 2.39 2.32 0.8
Median 2.25 2.5 2
Range 1–3.5 0–4 1–3.5
T2 lesion volume
Mean 8,640 7,502 7,253 0.7
Median 5,853 5,130 4,239
Range 155–45,417 223–44,135 272–54,041
T1-hypointense lesion volume
Mean 2,663 2,260 1,627 0.2
Median 1,004 979 690
Range 0–12,432 0–15,002 0–10,378
CL/patient
Mean 3.6 4.19 4.81 0.4
Median 3 3 2
Range 1–13 1–24 1–20
Gd enhancing CL/patient
Mean 2.46 3 3.5 0.4
Median 1 2 1.5
Range 0–9 0–23 0–14
ABH/patient
Mean 1.98 2.46 2.67 0.5
Median 1 1 1
Range 0–9 0–15 0–13
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slices were acquired with a matrix of 256 9 256 and field of
view of 250.
MRI analysis
MR images from all sites were gathered in the Medical
Image Analysis Centre (MIAC, Basel University Hospital,
Basel, Switzerland) and underwent quality control from
qualified personnel. MR images of patients with C1 can-
didate lesion were re-analyzed by one experienced rater
(AP), blinded to treatment assignment. CL were defined as
new lesions on MRI scans at week 8, compared with the
screening MRI (week 0) and at week 16, compared with
week 8; the presence and type of gadolinium (Gd)
enhancement of CL was also recorded. CL were deter-
mined at weeks 8 and 16 and not at week 0, to assure
that they were truly new lesions and to allow treatment to
exert its effect. CL were further tracked at week 16 (those
from week 8), week 28 and 48 and the lesions’ signal
intensity on the T1-w pre-contrast SE, compared to sur-
rounding normal appearing white matter (NAWM) was
recorded (T1-isointense: signal intensity similar to NAWM
and T1-hypointense: signal intensity lower than NAWM).
T1-hypointense lesions should be sharply demarcated;
diffuse, very mildly hypointense areas and areas with fuzzy
borders were considered T1-isointense. T1-hypointense
lesions at baseline (time-point of first detection of CL, i.e.,
week 8 or 16) were considered ABH and T1-hypointense
lesions at week 48 were considered PBH; PBH were small,
if their longest diameter was \5 mm and large, if their
longest diameter was C5 mm; they were strongly hypoin-
tense, if their signal intensity was similar to the CSF and
mildly hypointense, if it was similar to normal appearing
grey matter.
A repeat evaluation of T1-signal intensity at week 0 and
week 48 in a sample of 50 lesions was performed by the
same rater (AP), 6 months after the first evaluation. The
intra-rater agreement for ABH and PBH was 96%, with an
intra-class correlation coefficient (ICC) value of 0.90 (95%
CI 0.85–0.93).
Statistics
Demographic, clinical, and MRI characteristics at week 0
and MRI characteristics at week 8 or 16 were compared
between the three study arms using one-way ANOVA for
continuous variables and a proportion test for the cate-
gorical variable gender.
We used generalized estimating equation (GEE) models
with binomial error distribution to analyze the binary
endpoint ‘‘incidence of a PBH’’ at week 48 for all CL being
tracked. GEE models allow accounting for the fact that
lesions are clustered within patients. Treatment with BHT-
3009 was used as three-level explanatory factor.
The same type of model was used for the exploratory
analyses, i.e. analyzing the subgroups of Gd enhancing CL
only (n = 462) and ABH only (n = 367) and analyzing the
incidence of large PBH and of strongly hypointense PBH
for all CL.
To investigate the combined effects of pre-treatment anti-
MBP immune responsiveness and treatment with BHT-
3009, the natural logarithm of NUM (number of detected
MBP peptides), hereafter referred to as ‘‘log (antibodies)’’,
and the interaction: ‘‘log (antibodies) 9 BHT-3009 treat-
ment’’ were used as additional terms in the model.
Results
A total of 650 CL were found in 155 patients of the phase II
study. The total number of CL, and the proportions of Gd
enhancing CL, ABH, and PBH in each treatment group are
shown in Table 2.
We observed that the initial T1-signal-intensity of CL
(ABH or not at week 8 or 16) was highly predictive of the
outcome at week 48: the probability for a lesion to be PBH
Table 2 Total number of candidate lesions (CL) as well as numbers and proportions of gadolinium (Gd)-enhancing CL, acute black holes
(ABH), and persistent black holes (PBH) in the three treatment groups
Placebo 0.5 mg BHT-3009 1.5 mg BHT-3009
650 CL (patients’ n = 155) 180 (patients’ n = 50) 239 (patients’ n = 57) 231 (patients’ n = 48)
Gd-enhancing CL
Gd-enhancing CL/CL (%)
123
68
171
72
168
72
ABH
ABH/CL (%)
99
55
140
59
128
55
PBH
PBH/CL (%)
45
25
48
20
45
19
PBH/ABH (%) 45 34 35
Note that ABH were the candidate lesions that appeared as T1-hypointense at baseline (time-point of their first detection, i.e., week 8 or 16)
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at week 48 was much higher if it had been an ABH at
baseline (odds ratio = 10.2, p \ 0.001).
No effect of treatment with BHT-3009 was found on the
evolution of CL to PBH. Odds-ratio estimates for the
effects of low- (0.5 mg) and high-dose (1.5 mg) BHT-3009
treatment versus placebo on the risk of PBH are shown in
Fig. 1. Although odds-ratio estimates for both BHT-3009
treatment groups were below 1, no significant difference
could be shown even when both active treatment groups
(high- and low-dose BHT-3009) together were compared
with placebo. In line with this, our exploratory analysis
neither showed a significant effect of BHT-3009-treatment
on the risk of developing PBH in the subgroups of
Gd-enhancing CL and ABH (Fig. 1), nor on the risk of
developing large or strongly hypointense PBH.
However, we found a significant interaction between
treatment with BHT-3009 and the level of pre-treatment
serum anti-MBP antibodies [‘‘log (antibodies)’’] (Table 3;
Fig. 2). Patients receiving 0.5 mg BHT-3009 showed a
reduced risk of developing PBH with higher levels of anti-
MBP antibodies, compared to placebo (p \ 0.01 for the dif-
ference in slopes). On the contrary, patients receiving 1.5 mg
BHT-3009 showed a tendency for an increased risk of
developing PBH with higher antibody levels, but the difference
from placebo was not statistically significant. The outcome in
patients receiving placebo was not affected by anti-MBP-
antibody levels. Similar results were found when this analysis
was performed in the subgroup of ABH (Table 3).
Fig. 1 Odds-ratio estimates with 95% CI for the effects of low-
(0.5 mg) and high-dose (1.5 mg) BHT-3009 versus placebo on the
incidence of PBH. A 95% CI of the odds ratio including 1
corresponds to a non-significant difference. Odds ratios were
calculated by GEE models including all CL or the subgroups of
gadolinium-enhancing CL (GD?) and acute black holes (ABH) only
Table 3 Chi-square tests for the effects of treatment with BHT-3009,
level of pre-treatment serum anti-MBP antibodies, and the interaction
between the two on the incidence of persistent black holes (PBH)
df v2 p
Analysis including all CL
Treatment with BHT-3009 2 0.85 0.65
Log (antibodies) 1 0.49 0.49
Treatment with BHT-3009 9 Log
(antibodies)
2 14.36 0.0008
Analysis in the subgroup of ABH
Treatment with BHT-3009 2 0.57 0.75
Log (antibodies) 1 0.2 0.65
Treatment with BHT-3009 9 Log
(antibodies)
2 8.27 0.016
MBP myelin basic protein, CL candidate lesions, ABH acute black
holes df degrees of freedom
Chi-square tests are derived from ‘‘Analysis of Wald statistic tables’’
(GEE analogue to the ANOVA table)
Fig. 2 Association between the probability of a CL developing into a
PBH and the pre-treatment levels of anti-MBP antibodies (on a
logarithmic scale) in all three treatment arms. The curves show the
association between the probability of a CL developing into a PBH
and the pre-treatment level of anti-MBP antibodies (on a logarithmic
scale) by BHT-3009 treatment (indicated by color), as estimated by
the logistic GEE model. The transparent, filled circles represent the
observed CLs that either did or did not develop into PBH, taking a
value of 1 or 0 for the probability of PBH, respectively. To improve
legibility, the circles are jittered around 0 and 1. This analysis
included a total of 189 CLs from 46 patients with available anti-MBP
antibody data. Darker circles represent multiple CLs. Note that the
most effective treatment changes as we move along the range of anti-
MBP antibody levels, which is also reflected by the significant
interaction between ‘‘treatment with BHT-3009’’ and ‘‘log (antibod-
ies)’’ shown in Table 3
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Finally, the 46 patients were divided into two subgroups
based on the number of MBP peptides detected by IgM
antibodies (NUM: \12 vs. C12), to compare a potential
treatment effect in the subgroup with higher antibody
levels. This cut-off was chosen because it divides the data
set into two groups of similar size and also roughly coin-
cides with the intersection of lines in Fig. 2. However, we
could not show a significant difference in the effect of
BHT-3009 on the risk of PBH between these two patient-
subgroups.
Discussion
In this post hoc analysis, we examined the evolution of new
lesions to persistent black holes under treatment with BHT-
3009, an experimental DNA vaccine for MS patients, to
investigate a potential treatment effect on promoting focal
tissue repair. Although we observed in both BHT-3009
treated groups numerically lower proportions of PBH/CL
and PBH/ABH (Table 2) and odds ratio estimates below 1
(Fig. 1), these differences were not statistically significant.
Given the sample size, which included only a relatively
small (n = 155) subgroup of the initially 289 randomized
patients in the phase II study, it was not likely that we
would be able to see statistically significant results. How-
ever, despite the small number of patients, we found a
significant correlation between pre-treatment anti-MBP
antibody responses and effect of BHT-3009 on the reduc-
tion of risk of PBH. Most interestingly, the role of pre-
treatment serum antibody levels depended on the treatment
group: in patients under placebo, antibody levels hardly
affected the risk of PBH; however, in patients on 0.5 mg
BHT-3009 anti-MBP antibodies seemed to play a positive
role, since we observed a significant reduction in the risk of
PBH compared with placebo, with increasing antibody
levels. On the contrary, higher antibody levels tended to be
associated with a higher risk to develop PBH in patients on
1.5 mg BHT-3009 (however difference from placebo not
statistically significant). These results indicate that pre-
treatment serum anti-MBP IgM levels could be used to
identify populations of MS patients in which low-dose
treatment with BHT-3009 might have a neuroprotective
effect, promoting focal tissue repair. The lack of a signif-
icant interaction between BHT-3009 treatment and the
binary variable C12 versus \12 positive anti-MBP anti-
bodies probably reflects the loss of statistical power that
results from transforming the continuous predictor ‘‘log
(antibodies)’’ into a binary predictor.
The interaction between reactivity against myelin basic
protein and treatment effect of low-dose BHT-3009 supports
the proposed mechanism of action of this DNA plasmid, as
an immuno-tolerating treatment in MS. It is assumed that the
pathogenesis of MS is largely due to antigen-specific
autoimmunity with an essential role of myelin-specific T
lymphocytes [30–32]. Our hypothesis is that after injection,
low-dose BHT-3009 can produce myelin basic protein
within antigen-presenting cells of the immune system and
tolerize the MBP-reactive pathogenic T cells, thus attenu-
ating the autoimmune disease process. Based on this, it is
logical to assume that patients with higher pre-treatment
immune responses against MBP would respond better to
low-dose BHT-3009 treatment. Our findings support this
hypothesis and are also consistent with the previously
reported correlation between higher serum anti-MBP anti-
body levels and reduction of new lesions and relapses after
1 year of treatment with 0.5 mg BHT-3009 [29].
The different results in the 1.5 mg group are quite inter-
esting. We observed a tendency for an increased risk of
developing PBH in patients with higher antibody levels in
this high dose group, as illustrated in Fig. 2. Thus, our
findings confirm that the high dose of BHT-3009 is not
effective in patients with higher pre-treatment immune
responses against MBP. The fact that the 1.5-mg dose of
BHT-3009 is ineffective has been already suggested by the
main results of the original phase II study, where a tendency
for higher clinical and MRI activity as well as an increase in
autoantibody reactivity in the CSF was observed in the
1.5-mg treatment arm [28]. This phenomenon of lack of
efficacy or even deterioration with higher doses is also
known from other antigen-specific therapies and might be
due to an induction of a Th1, instead of Th2 immune response
[33]. Our observation that this effect may be more pro-
nounced in patients with stronger immune responses (in this
case against MBP), makes sense. In these patients, the higher
dose of antigen may have led to an excessive formation of
MBP-antibody complexes in vivo, which result in over-
stimulation of the immune system and eventually to a more
destructive inflammation in the central nervous system,
reflected by more frequent formation of persistent black
holes. Another possibility is that BHT-3009 in a dose
of 1.5 mg contains relatively high numbers of residual,
consensus immunostimulatory cytosine-phosphate-guanine
(CpG) motifs. These motifs could induce interferon-c pro-
duction, causing an exacerbation of the disease and thus
eliminating the tolerogenic effect of the plasmid [28].
Our results suggest that not only inflammatory activity
but also focal tissue repair could depend on the relation of
low-dose antigen-specific treatment and high pre-treatment
immune response of the patients. This is important for two
reasons: (1) it is compatible with the assumed mechanism
of action of low-dose BHT-3009, at least in a specific
population of MS patients and (2) it suggests an association
between anti-inflammatory and neuroprotective treatment
effects in MS. The latest is in line with other studies show-
ing that immunomodulatory drugs reducing inflammatory
1380 J Neurol (2012) 259:1375–1382
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activity can also reduce the risk of new persistent black holes
[24, 25, 27, 34, 35].
It is interesting that the odds ratios of new lesions
becoming PBH are significantly higher for lesions that
initially appear as T1-hypointense. This emphasizes that
although the initial T1-hypointensity of a new lesion often
(approximately 60%) [23] resolves over time, it is still a
negative prognostic factor, which increases the risk of
persistent hypointensity.
In conclusion, we could not show a significant treatment
effect of BHT-3009 on the evolution of CL to PBH in
general. However, an effect of low-dose (0.5 mg) BHT-
3009 versus placebo in patients with high pre-treatment
levels of anti-MBP antibodies in serum is suggested. Such
dependence of treatment effect on the patients’ pre-treat-
ment immune responses needs further confirmation in
prospective studies but—being consistent with an immune-
tolerating mechanism of action of BHT-3009—encourages
further research with antigen-specific agents in MS.
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